These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 17602229

  • 21. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 22. TNF therapy for spondyloarthropathy: can we marshal the argument?
    Dawes PT, Packham JC, Mucklow JC.
    Rheumatology (Oxford); 2004 Sep; 43(9):1069-71. PubMed ID: 15280568
    [No Abstract] [Full Text] [Related]

  • 23. Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis.
    Boers M.
    Ann Rheum Dis; 2009 Jan; 68(1):1-2. PubMed ID: 19088258
    [No Abstract] [Full Text] [Related]

  • 24. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.
    Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
    [Abstract] [Full Text] [Related]

  • 25. Fibromyalgia in between: where do the musculoskeletal physicians and psychiatrists stand?
    Algül A, Basoglu C, Kiralp MZ, Ozçakar L.
    Acta Reumatol Port; 2008 Sep; 33(4):477-8. PubMed ID: 19107094
    [No Abstract] [Full Text] [Related]

  • 26. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF, Seipelt E, Zipp F, Paul F.
    Scand J Rheumatol; 2008 Mar; 37(5):397-9. PubMed ID: 18720264
    [No Abstract] [Full Text] [Related]

  • 29. 'It's magic stuff': the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication.
    Stockdale J, Goodacre L.
    Musculoskeletal Care; 2009 Sep; 7(3):162-77. PubMed ID: 19065621
    [Abstract] [Full Text] [Related]

  • 30. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment.
    Wendling D, Blagosklonov O, Streit G, Lehuédé G, Toussirot E, Cardot JC.
    Ann Rheum Dis; 2005 Nov; 64(11):1663-5. PubMed ID: 16227425
    [No Abstract] [Full Text] [Related]

  • 31. Evidence in support of the validity of the TNF brake hypothesis.
    Maksymowych WP.
    Ann Rheum Dis; 2013 Dec; 72(12):e31. PubMed ID: 23989987
    [No Abstract] [Full Text] [Related]

  • 32. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
    Kiltz U, Heldmann F, Baraliakos X, Braun J.
    Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
    [Abstract] [Full Text] [Related]

  • 33. Restoration of overexpressed variable heavy chain 2 transcripts with tumor necrosis factor inhibitors in ankylosing spondylitis.
    Sheen DH, Kim JY, Lee SY, Lim MK, Yoo SJ, Yoo IS, Kim J, Kang SW, Shim SC.
    J Rheumatol; 2014 Mar; 41(3):613-4. PubMed ID: 24585525
    [No Abstract] [Full Text] [Related]

  • 34. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R, Assessment of SpondyloArthritis international Society (ASAS).
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [Abstract] [Full Text] [Related]

  • 35. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Gómez-Acebo I, Blanco R, Ochoa R, Rueda-Gotor J, Pina T, González-Juanatey C, Llorca J, González-Gay MA.
    Ann Rheum Dis; 2014 May; 73(5):941-3. PubMed ID: 24323393
    [No Abstract] [Full Text] [Related]

  • 36. Ankylosing spondylitis: recent developments and anaesthetic implications.
    Woodward LJ, Kam PC.
    Anaesthesia; 2009 May; 64(5):540-8. PubMed ID: 19413825
    [Abstract] [Full Text] [Related]

  • 37. Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab.
    Gomes KW, Benevides AN, Vieira FJ, Burlamaqui MP, Vieira Mde A, Fontenelle LM.
    Rev Bras Reumatol; 2012 May; 52(3):447-52. PubMed ID: 22641598
    [Abstract] [Full Text] [Related]

  • 38. Comment on: Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-alpha antagonist therapy: an ultrasound study.
    Knobloch K.
    Rheumatology (Oxford); 2010 Jul; 49(7):1418-9; author reply 1419-20. PubMed ID: 20360034
    [No Abstract] [Full Text] [Related]

  • 39. BSR guidelines for TNF blockers in ankylosing spondylitis--how useful are they?
    Sheehy C, Murphy E, Barry M.
    Rheumatology (Oxford); 2006 Sep; 45(9):1176-7; author reply 1177-8. PubMed ID: 16820380
    [No Abstract] [Full Text] [Related]

  • 40. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
    Montagna GL, Malesci D, Buono R, Valentini G.
    Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.